Related Experiment Video
Updated: May 30, 2026

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
Published on: November 25, 2025
Successful treatment of obsessive-compulsive disorder with zimelidine, a serotonin re-uptake inhibitor
1Registrar in Psychiatry, Royal Edinburgh Hospital, Edinburgh EH10 5HF, Scotland.
A 37 year old lady with severe obsessive-compulsive features which figured on Leyton's inventory was successfully treated with Zimelidine, a serotonin re-uptake inhibitor. Her response was rapid and associated with improvement in her mood. Two months later, she had still not relapsed and was maintaining her improvement.
A 37 year old lady with severe obsessive-compulsive features which figured on Leyton's inventory was successfully treated with Zimelidine, a serotonin re-uptake inhibitor. Her response was rapid and associated with improvement in her mood. Two months later, she had still not relapsed and was maintaining her improvement.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Management of Insomnia
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Psychosis: Goals of Pharmacotherapy
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
